Trial Profile
An Open-label, Multi-center, Phase IIIb Study for Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Nov 2015
Price :
$35
*
At a glance
- Drugs Decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Xian-Janssen
- 14 Nov 2015 Primary endpoint has been met. (Overall Response Rate (ORR): Number of Participants Who Achieved Either Complete Remission (CR), Partial Remission (PR), or Marrow Complete Remission (mCR) - International Working Group (IWG) 2006 Response Criteria), as per results published in the Advances in Therapy.
- 14 Nov 2015 Results published in the Advances in Therapy
- 17 Dec 2013 NCT reports actual actual end date as April 2013.